Invasive Lobular Carcinoma (ILC)
Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, after invasive ductal carcinoma (IDC). About 10% of all breast cancers are invasive lobular carcinomas, according to the American Cancer Society.
Invasive means the cancer has spread into surrounding breast tissues. Lobular means the cancer started in the lobules, the glands in the breast that produce milk. Carcinoma refers to any cancer that begins in the skin or other tissues that cover internal organs, such as breast tissue.
Symptoms of invasive lobular carcinoma
In many cases, invasive lobular carcinoma causes no symptoms and is found after your doctor sees a suspicious area on a screening mammogram.
In other cases, you or your doctor may feel a thick or swollen area in your breast. ILC is less likely than other breast cancers to cause a hard lump. Any of the following unusual changes in the breast can be a first sign of invasive lobular carcinoma:
swelling of all or part of the breast
skin dimpling, sometimes looking like an orange peel
breast or nipple pain
nipple discharge, other than breast milk
redness, scaliness, or thickening of the nipple or breast skin
a lump or swelling in the underarm area
Diagnosis of invasive lobular carcinoma
Diagnosing invasive lobular carcinoma involves a combination of procedures and almost always includes:
Other tests that may be used are:
Staging invasive lobular carcinoma
The stage of invasive lobular carcinoma is determined by the cancer’s characteristics, such as how large it is and whether or not it has hormone receptors. The stage of the cancer helps you and your doctor:
figure out your prognosis, which is the likely outcome of the disease
decide on the best treatment options for you
determine if certain clinical trials may be a good option for you
Generally, the stage of invasive lobular carcinoma is described as a number on a scale of I through IV. Stages I, II, and III describe early-stage cancers and stage IV describes cancers that have spread outside the breast to other parts of the body, such as the bones or liver.
Once a diagnosis of invasive lobular carcinoma has been made, your doctor will do more testing to collect information on the characteristics of the cancer. These tests, as well as the results of your biopsy, make up the parts of your pathology report.
Information commonly collected as part of a pathology report include:
size of the breast cancer
Nottingham grade of the cancer
lymph node status
hormone receptor status
rate of cell growth (Ki-67 levels)
Treatment of invasive lobular carcinoma
Treatments for invasive lobular carcinoma may include:
surgery: You and your doctor will work together to determine the type of surgery that’s right for you, based on the characteristics of the cancer, your family and medical history, and your preferences.
radiation therapy: Radiation therapy is almost always recommended after lumpectomy and may be recommended after mastectomy if the cancer is large or cancer is found in the lymph nodes.
chemotherapy: Chemotherapy may be given before or after surgery. Your doctor will consider the characteristics of the breast cancer and your medical history when deciding if chemotherapy is right for your unique situation.
hormonal therapy: If the breast cancer has receptors for the hormones estrogen, progesterone, or both, your doctor likely will recommend hormonal therapy, which is also called anti-estrogen therapy or endocrine therapy. Hormonal therapy medicines work by lowering the amount of estrogen in the body or by blocking the action of estrogen on breast cancer cells.
targeted therapy: Targeted cancer therapies are treatments that target specific characteristics of cancer cells, such as a protein that allows the cancer cells to grow in a rapid or abnormal way. Some targeted therapies are antibodies that work like the antibodies made naturally by our immune systems. These types of targeted therapies are sometimes called immune targeted therapies.
immunotherapy: Immunotherapy medicines use the power of your body’s immune system to attack cancer cells. The characteristics of the cancer will determine if immunotherapy is a good treatment option for you.
Survivorship care after invasive lobular carcinoma treatment
Because of better diagnostic tests and advances in cancer treatments, more people are living longer than ever after being diagnosed with any type of cancer, including breast cancer. Experts estimate that there are more than 3.8 million breast cancer survivors in the United States.
Still, because of treatments they’ve received, many breast cancer survivors have a higher risk of developing other diseases as they age, including high blood pressure, heart disease, and osteoporosis. To make sure breast cancer survivors are regularly screened for these and other diseases, experts have developed the idea of survivorship care planning.
Survivorship care plans are written documents made up of two parts.
The first part is a treatment summary, a record of all the breast cancer treatments you’ve received.
The second part is basically a roadmap of what you can expect in the years after treatment, including any late or long-term side effects you might have, and a schedule of how you’ll be monitored for these side effects and other health conditions. This part of the survivorship care plan usually includes:
the tests you’ll have
which doctors will order the tests
a schedule of when the tests will be done
healthy living recommendations
resources, if you need more information
Learn more at Before Treatment: Planning Ahead for Survivorship.
Subtypes of invasive lobular carcinoma
There are several subtypes of invasive lobular carcinoma, often named for how the
cells look under a microscope.
Classic ILC is the most common form of invasive lobular carcinoma and is made up of small cancer cells that invade the stroma, the fatty tissue and ligaments that surround the breast ducts and lobules. Classic ILC cells tend to invade the stroma in a single-file pattern.
Solid ILC cells grow in large sheets with little stroma in between them.
Alveolar ILC cells grow in groups of 20 or more.
Tubulolobular ILC cells grow in a single-file pattern, but some of the cells also form small tube-like structures.
Pleomorphic ILC cells look different from classic ILC cells. The cells are larger and the cells’ nuclei — the core of each cell that contains its genetic material — look different from each other. Pleomorphic ILC also may be composed of signet ring cells, cells that are filled with mucus that pushes the nucleus to one side.
The symptoms, diagnosis, staging, treatment options, and survivorship care are the same for all ILC subtypes.
— Last updated on June 29, 2022, 3:06 PM